Insider Confidence Grows as Prelude Therapeutics Officer Buys Shares Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics, has acquired 100,000 shares worth $69,250, signaling confidence amid a tough year for the stock, which has fallen nearly 87%. The company maintains a strong liquidity position and analysts remain cautiously optimistic, awaiting further clinical data later in 2025.12